Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in a global measure of cognition (composite) · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Mood: depression (participant self‐report) · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Change in rates of admission to residential care－not measured · participants with early‐stage Alzheimer's disease and vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in measures of dementia severity－not measured · participants with early‐stage Alzheimer's disease and vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in self‐reported mood (Depression－caregiver) · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Change in capacity for activities of daily living · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Mood · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Change in rates of admission to residential care－not measured · participants with early‐stage Alzheimer's disease and vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in measures of dementia severity－not measured · participants with early‐stage Alzheimer's disease and vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in immediate verbal memory scores · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Change in self‐reported burden of care · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review
Change in a global measure of cognition－not measured · participants with early‐stage Alzheimer's disease and vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Occupational performance ‐ performance Canadian Occupational Performance Measure. Scale from: 0 to 10. · participants with early‐stage Alzheimer's disease and vascular dementia
1 finding from 1 review